A clinical research study for patients with proteinuric chronic kidney disease (CKD) is now enrolling participants.
(281) 845-9359
contact@linqresearchllc.com
About FLAIR
Thank you for your interest in FLAIR.
FLAIR is a clinical study of an investigational drug called AZD5718. The study is sponsored by AstraZeneca.
FLAIR is now enrolling patients with proteinuric Chronic Kidney Disease (CKD)
CKD is a common long-term condition where the kidneys do not work as well as they should. It can cause a number of complications and may reduce the life expectancy of people who suffer from the disease. A protein called albumin is found in the urine of patients with proteinuric CKD. Treatments that reduce the amount of albumin in urine have improved outcomes for patients with proteinuric CKD.
This study is being conducted to assess whether AZD5718 can reduce the amount of albumin in the urine of participants with proteinuric CKD. The study will also determine the most effective dose of AZD5718.
We are also aiming to investigate the additive effect of dapagliflozin (an antidiabetic drug that has been shown to slow down CKD progression in diabetic patients) on the amount of albumin in urine in patients both with and without diabetes when taken together with AZD5718.
The study will involve adult participants aged 18 years and older. FLAIR is a Phase 2b study.
Find a Study Center
Please use the map below to find a study center near you. Study centers will be added to the map once they begin enrolling participants. If there is no center that is enrolling in your location at the moment, please check back at a later stage.